Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
28.05. | TransCode Therapeutics appoints RNA expert to advisory board | 2 | Investing.com | ||
28.05. | TransCode Therapeutics beruft RNA-Experten in den Beirat | 1 | Investing.com Deutsch | ||
08.05. | TransCode Therapeutics, Inc.: TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported | 109 | PR Newswire | 15 patients treated across four escalating dose levels of TTX-MC138
No significant safety or dose limiting toxicities reported
10 patients remain on study with... ► Artikel lesen | |
05.05. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split | 222 | PR Newswire | BOSTON, May 5, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company committed to more effectively... ► Artikel lesen | |
TRANSCODE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
02.05. | TransCode Therapeutics approves reverse stock split to meet Nasdaq rules | 2 | Investing.com | ||
02.05. | TransCode Therapeutics approves 1-for-28 reverse stock split; shares fall | 2 | Seeking Alpha | ||
02.05. | TransCode Therapeutics genehmigt Aktienzusammenlegung zur Einhaltung der NASDAQ-Regeln | 3 | Investing.com Deutsch | ||
02.05. | Transcode Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
02.05. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces 1-for-28 Reverse Stock Split | 113 | PR Newswire | Split designed to achieve compliance with Nasdaq minimum bid price requirements
BOSTON, May 2, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ)... ► Artikel lesen | |
01.05. | TransCode Therapeutics, Inc.: TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer | 88 | PR Newswire | A total of 13 patients treated with four escalating doses of TTX-MC138
No significant safety or dose limiting toxicities reported
Two patients have so far maintained... ► Artikel lesen | |
01.05. | EXCLUSIVE: TransCode Therapeutics Reports Progress In Early-Stage Study For Lead Cancer Drug | 3 | Benzinga.com | ||
30.04. | Transcode Therapeutics, Inc. - 10-K/A, Annual Report | 4 | SEC Filings | ||
21.04. | Transcode Therapeutics, Inc. - 8-K, Current Report | 13 | SEC Filings | ||
15.04. | Transcode Therapeutics, Inc. - 10-K, Annual Report | 6 | SEC Filings | ||
31.03. | Transcode Therapeutics, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 5 | SEC Filings | ||
27.03. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138 | 167 | PR Newswire | First patient in Cohort four has been treated with TTX-MC138
Ten patients have been treated with TTX-MC138 at escalating dose levels
Additional patients being... ► Artikel lesen | |
25.03. | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
25.03. | TransCode Therapeutics Announces $10M Stock And Warrant Offering | 1 | RTTNews | ||
24.03. | TransCode Therapeutics stock slides after announces to raise $10M securities offering | 5 | Seeking Alpha | ||
21.03. | TransCode Therapeutics Stock Surges 85% | 15 | RTTNews |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 99,25 | +1,79 % | Rheinmetall nicht zu bremsen! Evotec LEERVERKAUFT! Paukenschlag bei Vidac Pharma! Und was macht BioNTech Aktie? | Paukenschlag bei Vidac Pharma. Der Biotech-Highflyer des vergangenen Jahres hat starke Ergebnisse zu seinem Krebsmedikament veröffentlicht. Um 5 % ging es immerhin gestern nach oben. Ist die Konsolidierung... ► Artikel lesen | |
QIAGEN | 40,300 | -0,06 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Qiagen mit einem Kursziel von 48 Euro auf "Buy" belassen. Der Tenor auf der Berenberg-MedTech-Investorenkonferenz in Manhatten... ► Artikel lesen | |
NOVAVAX | 6,251 | -0,16 % | Schock-News für Novavax Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
PALATIN TECHNOLOGIES | 0,079 | -0,13 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
BRAIN BIOTECH | 2,070 | -1,43 % | BRAIN Biotech: Wann kommt die Trendwende bei den Biokatalysatoren? | Die BRAIN Biotech AG (DE0005203947) kämpft mit einem schwierigen Marktumfeld. Im ersten Halbjahr 2024/25 ging der Umsatz um 7,2 Prozent auf 25,2 Millionen Euro zurück. Das Unternehmen spürt die Auswirkungen... ► Artikel lesen | |
VIVOSIM LABS | 1,570 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
INOVIO PHARMACEUTICALS | 1,910 | 0,00 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
COSCIENS BIOPHARMA | 3,240 | -1,82 % | COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders | Reconstituted Board to Revitalize COSCIENS TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) today announced that it has entered into a resolution agreement... ► Artikel lesen | |
XOMA ROYALTY | 21,400 | -2,73 % | XOMA Royalty Corp - 8-K, Current Report | ||
T2 BIOSYSTEMS | 0,105 | -3,67 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
PHIO PHARMACEUTICALS | 2,085 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference | Marlborough, Massachusetts--(Newsfile Corp. - May 19, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary... ► Artikel lesen | |
MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
ORAGENICS | 3,560 | 0,00 % | Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split | SARASOTA, Fla., May 28, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotech company advancing innovative treatments for brain-related health conditions... ► Artikel lesen | |
LADRX | - | - | LadRx Corp - 10-Q, Quarterly Report | ||
VIVUS | - | - | Vivus' Qsymia gains market approval in UAE for obesity treatment |